BMS
JP Morgan Healthcare Conference Day 1: Novartis, Gilead, Johnson & Johnson, EQRx, Mirati, and More
Companies provided updates on precision oncology programs for CAR T-cell and biomarker-targeted therapies and announced plans for diagnostic and predictive tests.
Novartis' Kymriah Flops in Second-Line LBCL, Puzzling Oncologists After Yescarta, Breyanzi Successes
At ASH, researchers tried to explain why Novartis' CAR T-cell therapy failed to improve event-free survival for second-line LBCL patients whereas similar therapies succeeded.
CAR T-Cell Therapies Continue March Toward Earlier Lymphoma Treatment Lines, New ASH Data Show
Premium
Gilead's Yescarta and Bristol Myers Squibb's Breyanzi both showed second-line LBCL benefit over standard therapies in Phase III trials.
BMS, Inspirna to Study Yervoy, RGX-104 Combination in Endometrial Cancer
The trial will enroll patients with metastatic endometrial cancer who harbor APOE2 or APOE4 variants.
Bristol Myers Squibb Q3 Revenues Jump 10 Percent With Increased Sales in Oncology
Several precision cancer drugs in its oncology portfolio, including Opdivo, Yervoy, and CAR T-cell therapies, contributed to the revenue growth.